Buyback yield (TTM)
0.23%
Shareholder yield (TTM)
5.13%
5Y share count change
-5.0%
Buyback spend (TTM)
$376.01M
Cumulative buybacks
$43.86B
Key takeaways
- Novo Nordisk (NVO) repurchased about $376.01M of stock over the trailing twelve months.
- Diluted share count is down 5.0% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- Cash buyback spend has compounded at -39.3% per year over the latest 5-year window.
Dividend & buyback yield over time for Novo Nordisk (NVO)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Novo Nordisk (NVO)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Novo Nordisk (NVO)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Novo Nordisk (NVO)
Latest: $216.35M
Overview
2025's annual buyback spend for Novo Nordisk (NVO) came in at $1.39B – plunged 92.5% year-over-year.
Novo Nordisk buyback spend compound annual growth for the 2020–2025 (5 years) window is -39.6%, with a net decline across the window.
Novo Nordisk buyback spend peaked at $4.32B in 2023; the latest annual figure is $1.39B in 2025 (67.9% below peak).
Across the available history, buyback spend reached its high of $4.32B in 2023 and its low of $0.00 in 1990.
Novo Nordisk Buyback Spend 2025: $216.35M
2025's buyback spend for Novo Nordisk came in at $216.35M, plunged 93.1% below 2024.
Novo Nordisk Buyback Spend 2024: $2.89B
Novo Nordisk posted buyback spend of $2.89B in 2024, plunged 32.6% below 2023.
Novo Nordisk Buyback Spend 2023: $4.32B
In 2023, Novo Nordisk reported buyback spend of $4.32B, grew 24.2% from 2022. This figure represents the highest annual value in the available history.
Novo Nordisk Buyback Spend 2022: $3.31B
Novo Nordisk buyback spend in 2022 was $3.31B, grew 23.9% from 2021.
Novo Nordisk Buyback Spend 2021: $2.99B
Novo Nordisk buyback spend in 2021 was $2.99B.
See more financial history for Novo Nordisk (NVO).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $216.35M | $0.00 | $216.35M | 0.10% | 4.45B | -0.3% | |
| 2024 | $2.89B | $327.34M | $2.56B | 0.73% | 4.46B | -0.7% | |
| 2023 | $4.32B | $310.18M | $4.01B | 0.97% | 4.49B | -1.1% | |
| 2022 | $3.31B | $211.46M | $3.10B | 1.14% | 4.54B | -1.3% | |
| 2021 | $2.99B | $159.88M | $2.83B | 1.16% | 4.61B | -1.6% | |
| 2020 | $2.70B | $131.91M | $2.57B | 1.71% | 4.68B | -1.6% | |
| 2019 | $2.27B | $53.80M | $2.22B | 1.68% | 4.76B | -1.9% | |
| 2018 | $2.38B | $63.29M | $2.32B | 2.15% | 4.85B | -2.2% | |
| 2017 | $2.67B | $46.21M | $2.62B | 2.03% | 4.96B | -2.2% | |
| 2016 | $2.18B | $53.32M | $2.13B | 2.36% | 5.07B | -1.7% | |
| 2015 | $2.52B | $64.88M | $2.46B | 1.68% | 5.16B | -2.0% | |
| 2014 | $2.46B | $62.25M | $2.40B | 2.15% | 5.26B | -2.4% | |
| 2013 | $2.54B | $74.66M | $2.47B | 2.62% | 5.39B | -2.3% | |
| 2012 | $2.07B | $53.58M | $2.02B | 2.36% | 5.52B | -3.2% | |
| 2011 | $1.92B | $0.00 | $1.92B | 2.84% | 5.70B | -2.6% | |
| 2010 | $1.73B | $0.00 | $1.73B | 2.63% | 5.85B | -3.1% | |
| 2009 | $1.29B | $0.00 | $1.29B | 3.31% | 6.04B | -3.0% | |
| 2008 | $837.82M | $0.00 | $837.82M | 2.80% | 6.23B | -2.1% | |
| 2007 | $940.83M | $0.00 | $940.83M | 2.31% | 6.36B | -1.6% | |
| 2006 | $519.16M | $0.00 | $519.16M | 1.98% | 6.46B | -2.0% | |
| 2005 | $480.45M | $0.00 | $480.45M | 2.61% | 6.59B | -3.0% | |
| 2004 | $349.01M | $0.00 | $349.01M | 2.00% | 6.79B | -1.3% | |
| 2003 | $269.03M | $0.00 | $269.03M | 1.96% | 6.88B | -1.5% | |
| 2002 | $0.00 | $0.00 | $0.00 | 0.61% | 6.98B | +0.7% | |
| 2001 | $0.00 | $0.00 | $0.00 | 0.03% | 6.94B | -0.1% | |
| 2000 | $0.00 | $0.00 | $0.00 | — | 6.94B | -1.1% | |
| 1999 | $0.00 | $0.00 | $0.00 | — | 7.02B | -4.5% | |
| 1998 | $0.00 | $0.00 | $0.00 | — | 7.35B | -2.5% | |
| 1997 | $0.00 | $0.00 | $0.00 | — | 7.54B | +0.9% | |
| 1996 | $0.00 | $0.00 | $0.00 | — | 7.47B | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2025$216.35M
- 2024$2.89B
- 2023$4.32B
- 2022$3.31B
- 2021$2.99B
- 2020$2.70B
- 2019$2.27B
- 2018$2.38B
- 2017$2.67B
- 2016$2.18B
- 2015$2.52B
- 2014$2.46B
- 2013$2.54B
- 2012$2.07B
- 2011$1.92B
- 2010$1.73B
- 2009$1.29B
- 2008$837.82M
- 2007$940.83M
- 2006$519.16M
- 2005$480.45M
- 2004$349.01M
- 2003$269.03M
- 2002$0.00
- 2001$0.00
- 2000$0.00
- 1999$0.00
- 1998$0.00
- 1997$0.00
- 1996$0.00
- 1995$0.00
- 1994$0.00
- 1993$0.00
- 1992$0.00
- 1991$0.00
- 1990$0.00
Buybacks vs stock-based compensation for Novo Nordisk (NVO)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: N/A.
Buybacks vs dividends (share of cash returned) for Novo Nordisk (NVO)
How Novo Nordisk splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Novo Nordisk, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $3.00B | |
| $980.00M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $0.00 (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation